

March 23rd, 2021

Subject: Introduction of Fibryga® Kit: Now Co-Packaged with Water for Injection

Dear Health Care Professional,

Octapharma Canada is pleased to announce that Fibryga® (Fibrinogen Concentrate, Octapharma) kit will now include co-packaged sterile Water For Injection (WFI).

The new Fibryga Kit will include:

- 1gram of Lyophilised Fibrinogen concentrate as powder
- 50 ml sterile Water For Injection (WFI)
- 1 transfer device (Octajet) to reconstitute
- A particle filter
- Package leaflet



With everything you need to reconstitute Fibryga in one comprehensive kit, stocking Fibryga will simplify managing inventory and greatly improve your reconstitution experience.

Indication:

Fibryga® is indicated for the treatment of acute bleeding episodes and perioperative prophylaxis in adult and pediatric patients with congenital afibrinogenemia and hypofibrinogenemia.

Fibryga® is also indicated for the management of bleeds in Acquired Fibrinogen Deficiency (AFD)

New Infusion rate: Important changes have been made to the dosing and infusion rate of Fibryga¹. The standard dose of 4 g in AFD can be infused in 10 minutes (maximum rate of 20 mL per minute)¹. The ability to rapidly infuse Fibryga® 75% faster can be meaningful in urgent surgical situations. Further, Fibryga® can be reconstituted within approximately 5 minutes using the included Octajet® transfer device.

Room temperature storage and handling: Fibryga® can be stored at +2°C to +25°C for up to 36 months from the date of manufacture. After reconstitution Fibryga® is stable for up to 24 hours at +25°C.

Fibryga® co-packaged kit is available for ordering using the standard CBS product order form. Orders can be placed starting in April.

Octapharma Canada Inc.
214 King Street West
Suite 308
Toronto, ON M5H 3S6

Phone: (416) 531-5533
Email: info@octapharma.ca

Request more information or an in service:

To request a presentation, or a product demo or to obtain more information about Fibryga, HCPs can visit the self-service portal [here. www.fibrygaresources.ca](http://www.fibrygaresources.ca)

**Important Safety Information:**

As with all fibrinogen preparations, Fibryga® is contraindicated in patients who have manifested severe immediate hypersensitivity reactions, including anaphylaxis to any product ingredient or component of the container.

For complete prescribing information, refer to the complete Fibryga® Product Monograph. For additional information on Fibryga® please visit our www.fibrygaresources.ca or if you have any medical inquiries please contact medical information service by email medinfo.canada@octapharma.com or call 1-888-438-0488.

Sri Adapa
General Manager

References:

- 1) Fibryga® Product Monograph, November 19, 2020

Octapharma Canada Inc.
214 King Street West
Suite 308
Toronto, ON M5H 3S6

Phone: (416) 531-5533
Email: info@octapharma.ca
